Human study PLS-00242

FRDA Investigator Initiated Study (IIS) With Elamipretide

Other design · 20 participants enrolled

Version 1 · published November 8, 2026 · evidence through November 8, 2026 · research snapshot 2026.1.1 · methodology ev-1 · Automated assessment by AI (claude-opus-5-5 and claude-sonnet-5-5), not reviewed by a person.

Reports of this study

Every publication, registration and abstract describing this one study. Participants are counted once.

FRDA Investigator Initiated Study (IIS) With Elamipretideregistry entry · NCT05168774 (COMPLETED, results posted, planned enrollment 20)

Design and participants

Design: Other design
Population: People with Friedreich ataxia
Conditions: Friedreich Ataxia
Planned enrollment (registry): 20
Enrolled: 20
Randomized: Not reported
Completed follow-up: Not reported

Intervention and comparator

What each group received. Related peptides, analogs and combinations are never treated as the compound itself.

Elamipretide (intervention) · elamipretide · Elamipretide (also listed as MTP-131 / SS-31) · Not reported assigned

What the authors reported

As stated in the sources. This is the authors’ account, not Peptide Library’s assessment.

Adverse events

None reported. That is not evidence of safety, and how safety was monitored isn’t described.

Peptide Library’s assessment

An automated assessment, made by AI separately from the authors’ conclusions and not reviewed by a person. How risk of bias is assessed.

Limitations

abstract only: Only registry fields are available. There is no publication, abstract or posted result data in the record, although the registry flags that results exist.
small or imprecise: The registry lists an actual enrollment of only 20 participants, so any estimates would be imprecise.
other: The registry fields in the record do not state allocation, masking or a comparator. Design and control status cannot be determined.
selective reporting: The record lists no registered outcomes or results, so reported outcomes cannot be checked against the plan.
inappropriate population: The study enrolled people with Friedreich ataxia, not Barth syndrome or primary mitochondrial myopathy.

No risk-of-bias assessment has been published for this study’s results.

Claims this study informs

Improves function in Barth syndrome: not eligible (wrong population) for “Muscle strength, exercise capacity and fatigue”
Improves exercise capacity in primary mitochondrial myopathy: not eligible (wrong population) for “Six-minute walk distance and fatigue”
Is safe for human administration: not eligible (insufficient data) for “Adverse events, including injection-site reactions, and discontinuations”

Where each value comes from

arms: NCT NCT05168774, registry (interventions field) · extracted by AI (automated, not verified by a person)
design: NCT NCT05168774, registry (study_type and phases fields) · extracted by AI (automated, not verified by a person)
limitations: NCT NCT05168774, registry (has_results and enrollment fields) · extracted by AI (automated, not verified by a person)
participants: NCT NCT05168774, registry (enrollment and enrollment_type fields) · extracted by AI (automated, not verified by a person)
population: NCT NCT05168774, registry (conditions field) · extracted by AI (automated, not verified by a person)

Version 1 · published November 8, 2026 · evidence through November 8, 2026 · research snapshot 2026.1.1 · methodology ev-1 · Automated assessment by AI (claude-opus-5-5 and claude-sonnet-5-5), not reviewed by a person.

These assessments describe published research. Records marked automated were produced by AI under the published methodology and have not been reviewed by a person; they can contain errors. None of this is medical advice, not a statement about any product’s safety for human use, and not a regulatory approval. Peptide Library’s vendor and partner relationships play no part in them (editorial independence).